Literature DB >> 12767530

Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells.

Richard H Weisbart1, Carl W Miller, Grace Chan, Rika Wakelin, Kevin Ferreri, H Phillip Koeffler.   

Abstract

scFv fragments of a monoclonal antibody that penetrates living cells and localizes in nuclei were designed as fusion proteins with C-terminal p53 peptides and tested for restoring p53 function in p53 mutant cancer cells. scFv fragments transported a 30-mer C-terminal peptide of p53 into cancer cells and induced cellular cytotoxicity in contrast to scFv fragments alone and other scFv-p53 fusion peptides. Cellular toxicity was not observed with scFv fragments containing a single mutation in VH that prevented antibody penetration. Our results demonstrate the potential efficacy of antibody scFv fragments as a nuclear delivery system in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767530     DOI: 10.1016/s0304-3835(03)00151-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats.

Authors:  Xinhua Zhan; Bradley P Ander; Isaac H Liao; James E Hansen; Chester Kim; Douglas Clements; Richard H Weisbart; Robert N Nishimura; Frank R Sharp
Journal:  Stroke       Date:  2010-01-14       Impact factor: 7.914

2.  Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response.

Authors:  Hua-Wen Sun; Qi-Bing Tang; Yong-Jun Cheng; Sheng-Qian Zou
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

Review 3.  [The use of p53 as a tool for human cancer therapy].

Authors:  V P Almazov; D V Kochetkov; P M Chumakov
Journal:  Mol Biol (Mosk)       Date:  2007 Nov-Dec

4.  Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy.

Authors:  Michael W Lawlor; Dustin Armstrong; Marissa G Viola; Jeffrey J Widrick; Hui Meng; Robert W Grange; Martin K Childers; Cynthia P Hsu; Michael O'Callaghan; Christopher R Pierson; Anna Buj-Bello; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2013-01-09       Impact factor: 6.150

Review 5.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.